Primary regulatory
Rapamune (sirolimus) oral solution and tablets, Prescribing Information.
U.S. Food and Drug Administration. Rapamune (sirolimus) oral solution and tablets, Prescribing Information. Revised August 2022. Reference ID 5033875.
U.S. Food and Drug AdministrationPublished 2022Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
research-rapa-02- Source code
- RAPA-02
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.